News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III
Shire (SHPGY)'s Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015
CEL-SCI (CVM) Receives Regulatory Clearance To Expand Its Phase 3 Head And Neck Cancer Trial Into Romania 1/26/2015
Ipsen (IPN.PA) Announces Topline Results Of Two Double-Blind Phase 3 Studies Of Dysport® In Lower Limb Spasticity In Children And In Adults 1/26/2015
Regeneron (REGN) Release: EYLEA® (aflibercept) Injection Recommended For Approval For The Treatment Of Visual Impairment Due To Macular Edema Secondary To Central Or Branch Retinal Vein Occlusion In The European Union 1/23/2015
ALPHAEON Begins Phase 3 Study For Its Neurotoxin, EVOSYAL 1/22/2015
Shire plc Release: Positive Response From European Decentralised Procedure For Elvanse Adult® (lisdexamfetamine dimesylate) In Adults With ADHD 1/22/2015
FDA Removes Partial Clinical Hold on CytRx Corporation (CYTR)'s Brain Cancer Trials 1/21/2015
Celator Pharmaceuticals, Inc. Receives FDA Fast Track Designation For CPX-351 For The Treatment Of Elderly Patients With Secondary Acute Myeloid Leukemia 1/20/2015
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Analyses Of Phase 3 MM-398 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/20/2015
Actavis (ACT), Gedeon Richter Ltd. (RIG2.F) Say Key Drug Cariprazine Effective on Schizophrenia Relapse 1/20/2015
Choroideremia Research Foundation Release: Groundbreaking Gene Therapy Trial Begins In Philadelphia 1/20/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
Clinical Study Results Presented At The 2015 Gastrointestinal Cancer Symposium Support Utility Of Trovagene's Precision Cancer Monitoring Platform In Colorectal And Pancreatic Cancer Patients 1/20/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Marathon Pharmaceuticals, LLC Receives FDA Fast Track Designation For Deflazacort As A Potential Treatment For Duchenne Muscular Dystrophy 1/19/2015
PharmaEngine, Inc. Announces Expanded Analyses Of Phase 3 MM-398 NAPOLI-1 Study Presented At The 2015 American Society of Clinical Oncology GI Substantiate The Positive Results Of MM-398 In Combination With 5-FU/LV 1/19/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Update On Phase 3 AFFINITY Trial Evaluating Custirsen In Men With Metastatic Castrate-Resistant Prostate Cancer 1/16/2015
J.P. Morgan: AstraZeneca PLC (AZN) CEO Says He's Not Worried About Pricing Pressure 1/15/2015
Janssen Pharmaceutical Inc. Release: Real-World Data Published In Clinical Cardiology Show Consistent Safety Performance Of Once-Daily XARELTO® 1/14/2015
Bristol-Myers Squibb Company (BMY) Study Halted After Opdivo Meets Efficacy Endpoint 1/13/2015
Frost & Sullivan Releases Drug Launch And Phase 3 Trial Watch List For Top Therapeutic Areas 1/13/2015
Pharmamar Will Start A Phase 3 Study Of PM1183 In Combination With Doxorubicin In Relapsed SCLC 1/13/2015
Antares Pharma, Inc. (ATRS) Announces Update To QuickShot® Testosterone Program 1/13/2015
INSYS Therapeutics To Initiate Five Phase 3 Clinical Trials In 2015 1/13/2015
AB Science (AB.PA): The Data and Safety Monitoring Board Recommends The Continuation Of Phase 3 Study Of Masitinib In Amyotrophic Lateral Sclerosis 1/13/2015
Breaking: J.P. Morgan: BioMarin (BMRN) Takes Shot at Sarepta (SRPT), Says DMD Drug Has Better Results So Far 1/13/2015
J.P. Morgan: Celgene (CELG) to Fast-Track Crohn's Drug, Provides Estimates Up to 2020 1/13/2015
Radius (RDUS) Announces Follow-Up On The Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 1/12/2015
Portola Pharmaceuticals, Inc. Initiates Phase 4 Study To Support Accelerated Approval Of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote 1/12/2015
Tesaro, Inc. (TSRO) Announces Expansion Of Niraparib Clinical Program And Outlines Late-Stage Program Milestones For 2015 1/12/2015
The Lancet Oncology Publishes Phase 3 Data Showing Gilotrif® (Afatinib) Extends Overall Survival In Lung Cancer Patients Whose Tumors Have The Most Common EGFR Mutation Compared With Chemotherapy 1/12/2015
Aerie Pharmaceuticals, Inc. (AERI) Announces Acceleration Of Expected Timeline For Reporting Efficacy Results From Phase 3 Registration Trial (“Rocket 1”) Of Rhopressa™ 1/12/2015
The Lancet Oncology Publishes Phase III Data Showing Giotrif® (Afatinib*) Significantly Extended Overall Survival Of Lung Cancer Patients With The Most Common EGFR Mutation Over Chemotherapy 1/12/2015
Bristol-Myers Squibb Company (BMY) Release: CheckMate -017, A Phase 3 Study Of Opdivo (Nivolumab) Compared To Docetaxel In Patients With Second-Line Squamous Cell Non-Small Cell Lung Cancer, Stopped Early 1/12/2015
Regeneron (REGN), Sanofi (SAN.PA) Show Off Positive Cholesterol Drug Data 1/12/2015
GW Pharmaceuticals (GWPH) Falls as Cannabis Drug Fails Key Cancer Pain Study 1/9/2015
Regeneron (REGN) And Sanofi (SAN.PA) Announce Positive Topline Results From First Phase 3 Trials Evaluating Monthly Dosing Of Alirocumab In Patients With Hypercholesterolemia 1/9/2015
Portola Pharmaceuticals, Inc. Announces Phase 3 ANNEXA-R Study Of Andexanet Alfa And Factor Xa Inhibitor XARELTO® (Rivaroxaban) Met Primary Endpoint With High Statistical Significance 1/9/2015
Ligand Pharmaceuticals Inc. (LGND) Partner Retrophin (RTRX) Receives Orphan Drug Designation For Sparsentan 1/9/2015
Shield Therapeutics Announces The Publication Of The AEGIS Feraccru Phase 3 Pivotal Trial Manuscript In The Inflammatory Bowel Disease Journal 1/9/2015
AbbVie (ABBV), Neurocrine Biosciences, Inc. (NBIX) Drug Successful in Late Stage Endometriosis Trial 1/8/2015
Synergy Pharmaceuticals Completes Patient Enrollment For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 1/8/2015
Novartis AG (NVS) Announces Robust Phase 3 Results For QVA149 And NVA237 And Submits Regulatory Applications To U.S. FDA 1/8/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)'s Lead Candidate Delafloxacin Yields Positive Top-Line Results In Phase 3 Study In Patients With ABSSSI 1/8/2015
Dermira And UCB SA Announce Start Of Phase 3 Program For CIMZIA® (Certolizumab Pegol) In Psoriasis 1/8/2015
Versartis, Inc. (VSAR) Initiates Global Phase 3 Study Of VRS-317 In Children With Growth Hormone Deficiency 1/8/2015
Chimerix, Inc. (CMRX) Provides Update On Brincidofovir Pivotal Phase 3 Advise Trial For The Treatment Of Adenovirus 1/8/2015
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Analyses Of MM-398 Phase 3 NAPOLI-1 Study At The American Society of Clinical Oncology 2015 Gastrointestinal Cancers Symposium 1/8/2015
GW Pharmaceuticals (GWPH) And Otsuka Pharmaceutical Co., Ltd. Announce Results In First Of Three Sativex® Phase 3 Cancer Pain Trials 1/8/2015
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015
ContraVir Pharmaceuticals Granted FDA Meeting To Discuss Proposal For Phase 3 Trial Of FV-100 1/7/2015
Mirati Therapeutics  (MRTX) Doses First Patient In Investigator-Sponsored Phase 2 Study Of Mocetinostat In Non-Hodgkin's Lymphoma 1/6/2015
TONIX Pharmaceuticals, Inc. (TNXP) Provides Clinical And Regulatory Update On Its Continued Development Of TNX-102 SL In Fibromyalgia 1/6/2015
Alkermes plc (ALKS) Announces Positive Results From Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 1/6/2015
Versartis, Inc. (VSAR) Announces Positive 12 Month Data For VRS-317 from Ongoing Extension Study 1/5/2015
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015
Cerus Corporation (CERS) Reports EU Phase 3 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 1/5/2015
CEL-SCI (CVM)’s 2014 Patient Enrollment Increases Eight-Fold Over 2013 In Its Phase 3 Head And Neck Cancer Trial 1/5/2015
Cempra Pharmaceuticals, Inc. (CEMP) Surges as Lead Oral Antibiotic Meets Main Goal in Phase 3 Study 1/5/2015
Can-Fite BioPharma (CFBI) Completes The Design Of The Rheumatoid Arthritis Phase 3 Study Of Its Lead Drug Candidate Cf101 12/30/2014
Intersect ENT Announces Enrollment Of First Patient In Phase 3 Study Of In-Office Treatment For Recurrent Chronic Sinusitis 12/30/2014
Palatin Technologies (PTN) Announces Start Of Bremelanotide Phase 3 Program For Female Sexual Dysfunction 12/29/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX) Partner Submits Phase 2B/3 IND To Korean Health Authority For RGN-259 For The Treatment Of Dry Eye Syndrome 12/29/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/24/2014
Roche (RHHBY) Suffers A Double Blow As Breast Cancer, Alzheimer’s Drug Studies Fail; Pulls Plug On ALZ's Drug Development 12/23/2014
Provectus Biopharmaceuticals Inc. To Meet With FDA On Operational Aspects Of PV-10 Phase 3 Melanoma Study With Aim To Maximize Speed Of Enrollment 12/22/2014
Creative Bioarray Introduces Mini-Centrifuges With Outstanding Performance 12/22/2014
Radius (RDUS) Announces Positive Phase 3 Top-Line Results For Its Investigational Drug Abaloparatide-SC In Postmenopausal Women With Severe Osteoporosis 12/22/2014
TiGenix Submits Its Pivotal US Trial Design For Cx601 To The FDA For Special Protocol Assessment 12/22/2014
Receptos (RCPT) Initiates SUNBEAM Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis 12/22/2014
TetraPhase Pharmaceuticals (TTPH) Surges As Antibiotic Succeeds In Late-Stage Trial 12/19/2014
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine Hits Goal In Late-Stage Study 12/19/2014
Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/19/2014
ImmunoGen, Inc. (IMGN) Reports Roche (RHHBY) Has Provided An Update On The MARIANNE Trial 12/19/2014
Roche (RHHBY) Provides Update On Gantenerumab Development Programme 12/19/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
Cardio3 BioSciences Announces The Enrolment Of The 240th Patient For Its CHART-1 Phase 3 Clinical Trial For The Treatment Of Heart Failure 12/19/2014
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data 12/18/2014
Pivotal Phase 3 Study Of GlaxoSmithKline (GSK) Shingles Candidate Vaccine Meets Its Primary Endpoint 12/18/2014
Pfizer (PFE) Reports Top-Line Results From A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As A Treatment For Patients With Postherpetic Neuralgia 12/18/2014
TetraPhase Pharmaceuticals (TTPH) Announces Positive Top-Line Results From Phase 3 IGNITE 1 Clinical Trial Of Eravacycline In Complicated Intra-Abdominal Infections 12/18/2014
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial Of Plecanatide In Patients With Irritable Bowel Syndrome With Constipation 12/18/2014
LFB S.A. Announces Achievement Of Patient Enrollment Target For Persept 1 Program For The Evaluation Of Recombinant Factor Seven Efficacy By Prospective Clinical Trials 12/18/2014
Extab Corporation Announces Positive Data From Phase 3 Clinical Study Of Cytisine As A Smoking Cessation Aid Published In The New England Journal Of Medicine 12/18/2014
Hutchison Medipharma Starts Phase III Trial Of Cancer Drug 12/18/2014
RedHill Biopharma Ltd. (RDHL) Announces First Patients Enrolled In The Phase 3 Study Of RHB-102 (BEKINDA(TM)) For Gastroenteritis And Gastritis 12/17/2014
Sophiris Bio Inc. (SPHS) Tanks As Phase 3 Data Indicates Drug May Not Be Effective 12/16/2014
Celldex Therapeutics, Inc. (CLDX) Announces Completion Of Enrollment In Phase 3 Study Of Rindopepimut In Frontline Glioblastoma 12/16/2014
Cyclacel Pharmaceuticals, Inc. (CYCC) Announces Enrollment Of 486 Patients, DSMB Recommendations And That The Seamless Phase 3 Trial Of Sapacitabine In AML Will Continue To Final Analysis 12/16/2014
Ultragenyx Pharmaceuticals (RARE) Announces Initiation Of Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Mucopolysaccharidosis Type 7 12/15/2014
Sophiris Bio Inc. (SPHS) Reports Administrative Interim Analysis For The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 12/15/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Clinical Trial For Dalfampridine In Post-Stroke Walking Deficits 12/15/2014
Novartis AG (NVS) Psoriasis Drug Tops Johnson & Johnson (JNJ)'s Stelara In Late-Stage Study 12/12/2014
Nektar Therapeutics (CA) (NKTR) Presents Data On Target-Specific Biomarkers From Circulating Tumor Cell Sub-Study Of Phase 3 BEACON Study Of Etirinotecan Pegol (NKTR-102) In Patients With Advanced Breast Cancer 12/12/2014
BeyondSpring To Start China-U.S. Phase 3 Trial Of Novel Cancer Drug 12/12/2014
Ipsen (IPN.PA) Announces That The International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating The Use Of Ovarian Suppression To Adjuvant Treatment With Tamoxifen 12/12/2014
Alnylam Pharmaceuticals (ALNY) Initiates ENDEAVOUR Phase 3 Clinical Trial With Revusiran (ALN-Ttrsc), An Investigational RNAi Therapeutic Targeting Transthyretin (TTR) For The Treatment Of TTR Cardiac Amyloidosis 12/12/2014
Janssen Research & Development Release: Data From The EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented At San Antonio Breast Cancer Symposium 12/12/2014
Head-To-Head Psoriasis Study Demonstrates Superiority Of Novartis AG (NVS) Cosentyx™ To Stelara® In Clearing Skin 12/12/2014
Vectura Group plc (VEC.L)’s Investigational Drug/Device Combination VR475 Met Primary Endpoint And Has Shown Significant Clinical Benefit In A Phase 2b/3 Trial In Severe Asthma Patients 12/11/2014
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO)’s Brexpiprazole Demonstrates Statistically Significant Effects In New Phase 3 Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting 12/11/2014
Phase 3 Results From German Breast Group (GBG) Demonstrates Superior Activity In High Risk Early Breast Cancer For Nab-Paclitaxel (Abraxane®) Vs. Solvent-Based Paclitaxel 12/11/2014
Macrocure (MCUR) Announces Completion Of Mechanism Of Action Study 12/11/2014
Galena Biopharma  (GALE) Presents HER2 Screening Data Including Preliminary Leica Bond Oracle™ Results From the Phase 3 NeuVax™ (nelipepimut-S) Clinical Trial at the 2014 San Antonio Breast Cancer Symposium (SABCS) 12/11/2014
EXCLUSIVE: AbbVie (ABBV) VP Says New Cancer Drug Could Treat Other Diseases 12/11/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY) ADCETRIS Phase 3 Demonstrated Statistically Significant Improvement In Progression-Free Survival 12/10/2014
Bavarian Nordic (BAVA.CO) Reaches Enrollment Target In The Pivotal Phase 3 Study Of PROSTVAC® In Prostate Cancer 12/10/2014
Acorda Therapeutics (ACOR) Announces Initiation Of Phase 3 Trial Of CVT-301 In Parkinson’s Disease 12/10/2014
Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S (LUN.CO) Present Phase 3 Data On Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting 12/10/2014
Eli Lilly (LLY), Incyte Corporation (INCY) Arthritis Drug Meets Endpoint In Phase 3 12/10/2014
Bristol-Myers Squibb Company (BMY) Release: Anticoagulant Effect Of Eliquis (Apixaban) Reversed By Two Separate 4-Factor Prothrombin Complex Concentrates In Healthy Subjects 12/9/2014
New Data At American Society of Hematology 2014 Highlight Progress Of Pfizer (PFE)’s Growing Portfolio In Blood Cancers 12/9/2014
Celgene (CELG) Release: Data Presented On REVLIMID® (lenalidomide) Compared With Investigators’ Choice In Relapsed/Refractory Diffuse Large B-Cell Lymphoma 12/9/2014
Celgene (CELG) Release: Results From Phase 3 Study Of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence In Patients With Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented At American Society of Hematology 12/9/2014
Novartis AG (NVS) Release: Six-Year Pivotal Study Data Reinforce The Superiority Of Tasigna Over Gleevec In Newly-Diagnosed Patients With Ph+ CML 12/9/2014
New Trial Initiated Evaluating Amgen (AMGN)'s Talimogene Laherparepvec In Combination With Merck & Co. (MRK)'s Anti-PD-1 Therapy KEYTRUDA (Pembrolizumab) For Advanced Melanoma 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Shows Sustained Progression-Free Survival In Patients With High-Risk Chronic Lymphocytic Leukemia With Genetic Mutation 12/9/2014
CTI BioPharma Announces Presentation Of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance In FLT3-ITD Positive AML Cells 12/9/2014
ContraVir Pharmaceuticals Initiates Pharmacokinetic Study Of Lead Antiviral FV-100 For Treating Shingles 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: Results From Phase 3b Study Of POMALYST®/IMNOVID® (Pomalidomide) Plus Low-Dose Dexamethasone In Patients With Relapsed And Refractory Multiple Myeloma Presented At American Society of Hematology 12/9/2014
Celgene (CELG) Release: Additional Analyses Of High-Risk Patients From Phase 3 Study (AML-001) OF Vidaza® (Azacitidine For Injection) In Acute Myeloid Leukemia Presented At American Society of Hematology 12/9/2014
SSF's Sunesis Pharmaceuticals, Inc. (SNSS) Believes It Can End 40 Year AML Drought Despite "Failed" Phase 3 Study 12/8/2014
Phase 3 Data Shows Sandoz, Inc.'s Investigational Biosimilar Filgrastim Has Similar Safety And Efficacy As Amgen (AMGN)'s NEUPOGEN® 12/8/2014
Amgen (AMGN) And Onyx Pharmaceuticals, Inc. (ONXX) Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma 12/8/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Results From Phase 3 VALOR Trial At American Society of Hematology Annual Meeting 12/8/2014
CTI BioPharma Announces Comprehensive Kinome Analysis That Demonstrates Pacritinib Inhibits Kinases Linked To A Spectrum Of Blood-Related Cancers 12/8/2014
Novo Nordisk A/S (NVO) Release: Novoeight Phase 3 Data Show Reduction In Annualised Bleeding Rate Over Time In People With Haemophilia A 12/8/2014
American Society of Hematology Release: Novel Combinations Of New And Existing Therapies Yield Promising Results for Leukemia Patients With Poor Prognoses 12/8/2014
Vital Therapies, Inc. (VTI) (VTL) Announces First Subject Enrolled In VTI-210 And Provides Update On Enrollment In VTI-208 12/8/2014
BioDelivery Sciences International (BDSI) Announces Completion Of Randomization In Phase 3 Trial Of Clonidine Topical Gel For The Treatment Of Painful Diabetic Neuropathy 12/8/2014
Upsher-Smith Laboratories Presents New Data From Year-Long, Open-Label Extension Study Of Qudexy XR (Topiramate) Extended-Release Capsules At 68th Annual American Epilepsy Society Meeting 12/8/2014
Orexo Features Positive Results From The ISTART Study At The 2014 AAAP Meeting 12/8/2014
ACADIA Pharmaceuticals, Inc. (ACAD) Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson’s Disease And Related Disorders 12/8/2014
CEL-SCI (CVM) Expands Its Pivotal Phase 3 Immunotherapy Head And Neck Cancer Trial With Addition Of 7 More Clinical Sites 12/8/2014
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Report Phase 3 AETHERA Clinical Trial Data From ADCETRIS® (Brentuximab Vedotin) In Post-Transplant Hodgkin Lymphoma Patients At Risk Of Relapse At American Society of Hematology Annual Meeting 12/8/2014
ERYtech Pharma Reports Additional Positive Phase 3 Results From Clinical Study With ERY-ASP/GRASPA® In Acute Lymphoblastic Leukemia 12/8/2014
Celgene (CELG) Release: Age, Renal Impairment and Depth of Response Analyses of the First™ (MM-020/IFM 07-01) Study of Continuous REVLIMID® (Lenalidomide) Plus Low-Dose Dexamethasone In Newly-Diagnosed Multiple Myeloma Presented at American Society of Hematology 12/8/2014
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014
PaxVax, Inc. Announces Primary Endpoints Met In Phase 3 Cholera Vaccine Trial 12/8/2014
Novartis AG (NVS) Copy Of Amgen (AMGN) Cancer Drug Shows Similar Efficacy 12/8/2014
Amgen (AMGN)'s Kyprolis Delivers In Phase 3 Multiple Myeloma Study 12/8/2014
FDA Grants Breakthrough Therapy Status To Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Ixazomib 12/8/2014
Intercept Pharmaceuticals (ICPT) Announces Publication Of Meta-Analysis From The Global PBC Study Group In Gastroenterology 12/5/2014
CytRx Corporation (CYTR) Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials 12/4/2014
Phase 3 Results Published In The New England Journal of Medicine Show Superiority Of Pfizer (PFE)’s XALKORI® (crizotinib) Compared To Platinum-Based Chemotherapy In Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer 12/4/2014
Investors Cheer As Biogen Idec (BIIB)'s BIIB037 Skips To Phase 3 For Alzheimer's 12/4/2014
ADMA Biologics, Inc.'s Primary Endpoint Achieved, Touts Positive Phase 3 Data 12/3/2014
Novartis AG (NVS) Flu Vaccine FLUAD Suspended Following 13 Reported Deaths 12/3/2014
Novartis AG (NVS) Fingolimod Ph3 Trial In PPMS Fails To Meet Primary Goal 12/3/2014
Prothena Corporation plc Targets Rare Protein-Misfolding Disease In Late-Stage Study 12/3/2014
First MS Patients In The U.S. Receive Genzyme Corporation (GENZ)’s Lemtrada Following FDA Approval 12/3/2014
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Trial Of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 12/3/2014
Prothena Corporation plc Initiates NEOD001 Global Phase 3 Registrational Trial Based On Positive Results In Ongoing Phase 1/2 Study Of NEOD001 In Patients With AL Amyloidosis 12/3/2014
BeyondSpring Pharmaceuticals To Conduct Phase 3 Trial Of Lead Candidate Plinabulin In NSCLC 12/3/2014
Exelixis, Inc. (EXEL) COMET-2 Ph3 Cabozantinib Trial Fails To Meet Primary Endpoint 12/2/2014
Aerie Pharmaceuticals, Inc. (AERI) Completes Enrollment In Phase 3 Registration Trial ("Rocket 1") Of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 12/2/2014
CEL-SCI (CVM) Quarterly Patient Enrollment In Its Head And Neck Cancer Phase 3 Trial Increases Eight Fold Over Same Prior Year Period 12/2/2014
Exelixis, Inc. (EXEL) Announces Results From The COMET-2 Pivotal Phase 3 Trial Of Cabozantinib In Men With Metastatic Castration-Resistant Prostate Cancer 12/1/2014
Mylan Inc. (MYL), Gilead Sciences, Inc. (GILD) Ink Agreement Covering Non-Exclusive TAF Rights 12/1/2014
Celator Pharmaceuticals, Inc. Announces Data And Safety Monitoring Board Recommendation To Continue Phase 3 Study Of CPX-351 12/1/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback From European Medicines Agency On Advancing ICT-107 To Phase 3 Program 12/1/2014
AEterna Zentaris (AEZS) And Sinopharm A-Think Sign Master Collaboration Agreement For Zoptarelin Doxorubicin In China 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Zogenix, Inc. (ZGNX) Release: Results Of Long-Term, Open-Label Study Published In The Journal Of Pain Research Demonstrate The Safety, Tolerability And Effectiveness Of Zohydro ER 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Amgen (AMGN), AstraZeneca PLC (AZN)'s Brodalumab Phase 3 Study Met All Primary Endpoints Against Johnson & Johnson (JNJ)'s Stelara 11/26/2014
Amgen (AMGN) Terminates All Rilotumumab Clinical Trials For Advanced Gastric Cancer 11/26/2014
FDA Requires Additional Data On Bristol-Myers Squibb Company (BMY)' Hep C Daclatasvir 11/26/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Children With Spinal Muscular Atrophy 11/25/2014
R-Tech Ueno Received Orphan Drug Designation For Unoprostone Isopropyl (Development Code:UF-021) For The Treatment Of Retinitis Pigmentosa From MHLW 11/25/2014
Intra-Cellular Therapies, Inc. Announces Enrollment Of First Patient In Phase 3 Trial Of ITI-007 For The Treatment Of Schizophrenia 11/25/2014
Ferring Pharmaceuticals Release: New Data From A Pooled Analysis Shows Improved Overall Survival For Prostate Cancer Patients Treated With FIRMAGON® (Degarelix) Compared To LHRH Agonists 11/25/2014
Onxeo Announces Positive DSMB Recommendation For Its Phase 3 Trial With Livatag® In Primary Liver Cancer 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets FDA Breakthrough Therapy Designation 11/24/2014
Top 10 Countries For Diabetes Clinical Research 11/21/2014
Relypsa, Inc. (RLYP) Announces Data Published In The New England Journal of Medicine For Pivotal Phase 3 Program Of Patiromer FOS For The Treatment Of Hyperkalemia 11/21/2014
ZS Pharma (ZSPH) Announces Publication Of Results From Phase 3 Study Of ZS-9 In Patients With Hyperkalemia In The New England Journal of Medicine 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
Immunomedics, Inc. (IMMU) Presents Clinical Data On Novel Antibody-Drug Conjugates For Solid Cancer Therapy 11/21/2014
Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint 11/20/2014
Charleston Laboratories, Inc. And Daiichi Sankyo, Inc. (4568.t) Initiate Two Phase 3 Clinical Trials On Charleston's Lead Product, CL-108 11/20/2014
TrovaGene, Inc. Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations In Circulating Tumor DNA Of Colorectal Cancer Patients 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Titan Pharmaceuticals (TTP) Announces Completion Of Enrollment In Phase 3 Study Of Probuphine For Opioid Dependence 11/20/2014
Merrimack Pharmaceuticals Inc. (MACK) Receives FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer 11/19/2014
FDA Puts Partial Hold On CytRx Corporation (CYTR)'s Aldoxorubicin Clinical Trials 11/19/2014
SOTIO Initiates US Part Of VIABLE, A Global Phase III Clinical Trial For Prostate Cancer Immunotherapy Treatment With DCVAC/PCa 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
Genzyme Corporation (GENZ) And Isis Pharmaceuticals, Inc. (ISIS) Present KYNAMRO® Clinical Data At American Heart Association 11/19/2014
ZS Pharma (ZSPH) Presents Positive Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia, At The American Heart Association Scientific Meeting And Announces Simultaneous Publication Of Results In JAMA 11/17/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014
Novartis Pharmaceutical Corporation (NVS) AIN457 (secukinumab) Showed Significant Symptom Improvement In Two Pivotal Phase 3 ankylosing spondylitis Studies 11/17/2014
TissueGene, Inc. Receives Recommendations From FDA On Pathway To Phase 3 Trial Of TG-C For Treatment Of Osteoarthritis Of The Knee 11/17/2014
Keryx Biopharmaceuticals (KERX) Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study 11/17/2014
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology 11/17/2014



//-->